Business UpdateMay 19, 2026, 07:02 AM
EyePoint Management to Present at Three Upcoming Conferences
AI Summary
EyePoint, Inc. announced that its management will participate in three upcoming healthcare conferences. These include the Stifel 2026 Virtual Ophthalmology Forum on May 26, the Jefferies Global Healthcare Conference on June 3, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. Webcasts and replays of the fireside chats will be available on the company's investor website. EyePoint is a clinical-stage biopharmaceutical company focused on retinal diseases, with its lead candidate DURAVYU™ currently in Phase 3 trials for wet AMD and DME, with topline data for wet AMD expected mid-2026.
Key Highlights
- Management to participate in Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026.
- Management to participate in Jefferies Global Healthcare Conference on June 3, 2026.
- Management to participate in Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026.
- Webcasts and archived replays will be accessible via the company's investor website.
- Lead product candidate DURAVYU™ is in Phase 3 pivotal trials for wet AMD and DME.
- Topline data for wet AMD is expected beginning in mid-2026.
Price Impact
More from EYPT